Cargando…

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

There are limited data concerning the immunogenicity and reactogenicity of COVID-19 vaccines in children. A total of 110 children, 5–11 years old were vaccinated with two doses (with a 3-week interval between doses) of the Pfizer-BioNTech COVID-19 vaccine and were followed for 21, 90, and 180 days a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joseph, Gili, Klein, Elisheva, Lustig, Yaniv, Weiss-Ottolenghi, Yael, Asraf, Keren, Indenbaum, Victoria, Amit, Sharon, Kriger, Or, Gilboa, Mayan, Levy, Yuval, Pessach, Itai M., Kreiss, Yitshak, Regev-Yochay, Gili, Stein, Michal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693260/ https://www.ncbi.nlm.nih.gov/pubmed/36423049 http://dx.doi.org/10.3390/vaccines10111954

Ejemplares similares

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
por: Joseph, Gili, et al.
Publicado: (2023)

Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
por: Gilboa, Mayan, et al.
Publicado: (2022)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2022)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
por: Canetti, Michal, et al.
Publicado: (2023)

Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
por: Gilboa, Mayan, et al.
Publicado: (2023)

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
por: Barda, Noam, et al.
Publicado: (2022)

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021)

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
por: Regev-Yochay, Gili, et al.
Publicado: (2022)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk
por: Shavit, Ronen, et al.
Publicado: (2021)

Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
por: Regev-Yochay, Gili, et al.
Publicado: (2023)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

The Use of Rapid COVID-19 Antigen Test in the Emergency Department as a Decision-Support Tool
por: Meltzer, Lilac, et al.
Publicado: (2023)

Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
por: Barda, Noam, et al.
Publicado: (2023)

Screening for Asymptomatic Clostridioides difficile Carriage Among Hospitalized Patients: A Narrative Review
por: Gilboa, Mayan, et al.
Publicado: (2023)

Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring
por: Lai, Francisco Tsz Tsun, et al.
Publicado: (2022)

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients
por: Amit, Sharon, et al.
Publicado: (2021)

COVID-19 vaccine efficacy data: solid enough to delay second dose? – Authors' reply
por: Amit, Sharon, et al.
Publicado: (2021)

Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021)

Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021)

Pfizer-BioNTech COVID-19 vaccine safe in children
Publicado: (2022)

Tachycardia following Pfizer-BioNTech COVID-19 vaccine
por: Martins-Filho, Paulo Ricardo
Publicado: (2023)

Pfizer-BioNTech COVID-19 vaccine safe with clozapine
Publicado: (2022)

Tachycardia following Pfizer-BioNTech COVID-19 vaccine
por: Martins-Filho, Paulo Ricardo
Publicado: (2023)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

681. Antibiotic Treatment During Hospitalization Is a Major Risk Factor for The Occurrence Of Clostridium Difficile Infection Among Carriers
por: Gilboa, Mayan, et al.
Publicado: (2023)

Pfizer-BioNTech COVID-19 vaccine-related risk of anaphylaxis
Publicado: (2021)

Managing allergic reactions to Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021)

COVID-19-Vaccine-Pfizer-BioNTech: Thyroiditis: case report
Publicado: (2021)

Pfizer-BioNtech's COVID-19 vaccine approved for younger adolescents
Publicado: (2021)

Pfizer-BioNTech COVID-19 vaccine in patients with severe allergies
Publicado: (2021)

Anaphylaxis after Pfizer-BioNTech COVID-19 vaccine in Japan
Publicado: (2021)

COVID-19-Vaccine-Pfizer-BioNTech: Anaphylaxis: case report
Publicado: (2022)

COVID-19-Vaccine-Pfizer-BioNTech: Myocarditis: case report
Publicado: (2022)

No evidence of TTS risk with Pfizer/BioNTech's COVID-19 vaccine
Publicado: (2021)

Pfizer-BioNTech COVID-19 vaccine safe in older Koreans
Publicado: (2021)

Adverse reactions with Pfizer/BioNTech's COVID-19 vaccine in Ecuador
Publicado: (2021)

Pityriasis Rosea Following Pfizer-BioNTech Vaccination in an Adolescent Girl
por: Bin Rubaian, Nouf F, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hnuga51m58vulbkle9e5qpvvrn